- Home
- YETI vs BEAM Comparison
YETI vs BEAM Comparison
Compare YETI & BEAM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | YETI | BEAM |
|---|---|---|
| Founded | 2006 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Recreational Games/Products/Toys | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.1B | 3.0B |
| IPO Year | 2016 | 2019 |
Fundamental Metrics
Financial Performance| Metric | YETI | BEAM |
|---|---|---|
| Price | $47.76 | $29.54 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 12 | 12 |
| Target Price | $47.75 | ★ $50.75 |
| AVG Volume (30 Days) | 1.6M | ★ 1.8M |
| Earning Date | 05-14-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 82.31 |
| EPS | ★ 0.13 | N/A |
| Revenue | ★ $1,868,494,000.00 | $24,000.00 |
| Revenue This Year | $9.07 | N/A |
| Revenue Next Year | $7.11 | $33.77 |
| P/E Ratio | $367.85 | ★ N/A |
| Revenue Growth | 2.11 | ★ 33.33 |
| 52 Week Low | $29.12 | $15.60 |
| 52 Week High | $51.29 | $36.44 |
Technical Indicators
Market Signals| Indicator | YETI | BEAM |
|---|---|---|
| Relative Strength Index (RSI) | 63.24 | 47.89 |
| Support Level | $43.46 | $28.50 |
| Resistance Level | $49.90 | $33.15 |
| Average True Range (ATR) | 1.97 | 2.05 |
| MACD | 0.19 | -0.01 |
| Stochastic Oscillator | 80.67 | 40.12 |
Price Performance
Historical ComparisonAbout YETI YETI Holdings Inc.
YETI Holdings Inc is a designer, marketer, and distributor of premium products for the outdoor and recreation market sold under the YETI brand. The company offers products including coolers and equipment, drinkware, and other accessories. Its trademark products include YETI Tundra, Hopper, YETI TANK, Rambler, Colster, Rambler among others. The company distributes products through wholesale channels and through direct-to-consumer, or DTC, channels.
About BEAM Beam Therapeutics Inc.
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company operates and manages its business in one operating segment, United States.